K
Kelly E. Dooley
Researcher at Johns Hopkins University School of Medicine
Publications - 164
Citations - 6319
Kelly E. Dooley is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 33, co-authored 138 publications receiving 4852 citations. Previous affiliations of Kelly E. Dooley include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Tuberculosis and diabetes mellitus: convergence of two epidemics
TL;DR: A review of the evidence for the role of diabetes mellitus in susceptibility to, clinical presentation of, and response to treatment for tuberculosis can be found in this paper, where potential mechanisms by which diabetes can cause tuberculosis, the effects of tuberculosis on diabetic control, and pharmacokinetic issues related to the co-management of diabetes and tuberculosis.
Iconographies supplémentaires de l'article : Tuberculosis and diabetes mellitus: convergence of two epidemics
TL;DR: The epidemiology of the tuberculosis and diabetes epidemics is reviewed, and a synopsis of the evidence for the role of diabetes mellitus in susceptibility to, clinical presentation of, and response to treatment for tuberculosis is provided.
Journal ArticleDOI
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda,Tawanda Gumbo,Gary Maartens,Kelly E. Dooley,Ruth McNerney,Megan Murray,Jennifer Furin,Edward A. Nardell,Leslie London,Erica Lessem,Grant Theron,Paul D. van Helden,Stefan Niemann,Matthias Merker,David W. Dowdy,Annelies Van Rie,Annelies Van Rie,Gilman Kit Hang Siu,Jotam G. Pasipanodya,Camilla Rodrigues,Taane G. Clark,F. A. Sirgel,Aliasgar Esmail,Hsien-Ho Lin,Sachin R Atre,H. Simon Schaaf,Kwok Chiu Chang,Christoph Lange,Payam Nahid,Zarir F Udwadia,C. Robert Horsburgh,Gavin J. Churchyard,Gavin J. Churchyard,Dick Menzies,Anneke C. Hesseling,Eric L. Nuermberger,Helen McIlleron,Kevin P. Fennelly,Eric Goemaere,Ernesto Jaramillo,Marcus Low,Carolina Morán Jara,Nesri Padayatchi,Robin M. Warren +43 more
TL;DR: Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.
Journal ArticleDOI
Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis
TL;DR: In conclusion, DM was a risk factor for death in Maryland TB patients and there was a trend toward increased time to culture conversion; two-month culture conversion proportions, however, were similar.
Journal ArticleDOI
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Susan E. Dorman,Payam Nahid,Ekaterina V. Kurbatova,Patrick P. J. Phillips,Kia E Bryant,Kelly E. Dooley,Melissa Engle,Stefan V. Goldberg,Ha T.T. Phan,James Hakim,John L. Johnson,Madeleine Lourens,Neil A. Martinson,Neil A. Martinson,Grace Muzanyi,Kim Narunsky,Sandy Nerette,Nhung Viet Nguyen,Thuong H. Pham,Samuel Pierre,Anne E. Purfield,Anne E. Purfield,Wadzanai Samaneka,Radojka M. Savic,Ian Sanne,Nigel A. Scott,Justin Shenje,Erin Sizemore,Andrew Vernon,Ziyaad Waja,Marc H Weiner,Susan Swindells,Richard E. Chaisson +32 more
TL;DR: In this paper, Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.